Cargando…

Migrastatics—Anti-metastatic and Anti-invasion Drugs: Promises and Challenges

In solid cancers, invasion and metastasis account for more than 90% of mortality. However, in the current armory of anticancer therapies, a specific category of anti-invasion and antimetastatic drugs is missing. Here, we coin the term ‘migrastatics’ for drugs interfering with all modes of cancer cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandalovičová, Aneta, Rosel, Daniel, Fernandes, Michael, Veselý, Pavel, Heneberg, Petr, Čermák, Vladimír, Petruželka, Luboš, Kumar, Sunil, Sanz-Moreno, Victoria, Brábek, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482322/
https://www.ncbi.nlm.nih.gov/pubmed/28670628
http://dx.doi.org/10.1016/j.trecan.2017.04.008
Descripción
Sumario:In solid cancers, invasion and metastasis account for more than 90% of mortality. However, in the current armory of anticancer therapies, a specific category of anti-invasion and antimetastatic drugs is missing. Here, we coin the term ‘migrastatics’ for drugs interfering with all modes of cancer cell invasion and metastasis, to distinguish this class from conventional cytostatic drugs, which are mainly directed against cell proliferation. We define actin polymerization and contractility as target mechanisms for migrastatics, and review candidate migrastatic drugs. Critical assessment of these antimetastatic agents is warranted, because they may define new options for the treatment of solid cancers.